---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Pharmacodynamics"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Pharmacodynamics. Topics: H3K27me3 reduction in peripheral blood with single-agent dosing, H3K27me3 reduction in combination with darolutamide, Plasma cell-free DNA methylation in participants treated with single-agent rinzimetostat, Paired tumor biopsies in participants treated with single-agent rinzimetostat, and 5 further topics. 9 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### H3K27me3 reduction in peripheral blood with single-agent dosing

> “There was robust target engagement, with maximal decrease (≥75%) in H3K27me3 in monocytes from peripheral blood samples at doses as low as 200 mg QD with low inter-patient variability.”

Source: [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

<a id="topic-2.1.2.6.2-2"></a>

### H3K27me3 reduction in combination with darolutamide

> “Rinzimetostat pharmacokinetic and pharmacodynamic data were highly consistent as a single agent and in combination with darolutamide, and supportive of dose optimization of 400 mg and 600 mg QD”
> “monotherapy activity measured in monocytes derived”
> “combination activity measured in granulocytes derived from PBMCs”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.6.2-3"></a>

### Plasma cell-free DNA methylation in participants treated with single-agent rinzimetostat

> “Plasma cfDNA methylation profiling showed epigenetic shifts indicative of increased AR signaling after one treatment cycle in most patients assessed.”

Source: [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)

> “Plasma samples were collected at first day of treatment and after 28 days of rinzimetostat dosing. Cell free DNA was sequenced for DNA methylation with the PredicineALERT panel.”

Source: [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf)

<a id="topic-2.1.2.6.2-4"></a>

### Paired tumor biopsies in participants treated with single-agent rinzimetostat

> “Paired tumor biopsies showed increased levels of luminal and AR-associated markers PSMA and KLK2.”

Source: [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)

> “Tumor biopsies were collected at screening and after 2 cycles of treatment, with biopsy taken from prostate for patient 1 and lymph node for patient 2.”
> “KLK2 staining was not done for patient 2 due to depleted tissue.”

Source: [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf)

<a id="topic-2.1.2.6.2-5"></a>

### Preclinical synergy with androgen receptor pathway inhibitors

> “ORIC-944 synergizes with ARPI and extends progression-free survival in CRPC and CSPC models in vivo”

Source: [Daemen et al. (2025)](https://oricpharma.com/wp-content/uploads/2025/04/AACR2025_ORIC-944-poster_Final.pdf)

> “Synergistic cell viability effects are achieved when inhibiting PRC2 either with allosteric EED inhibition using ORIC-944 or EZH2 inhibition using mevrometostat.”

Source: [Yuen et al. (2025)](https://oricpharma.com/wp-content/uploads/2025/10/ENA2025_ORIC-944-ARi-CSPC-Poster.pdf)

> “Rinzimetostat in combination with ARPI darolutamide demonstrated antitumor activity across a breadth of in vivo models representing the prostate cancer continuum”

Source: [Pankov et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/08/Rinzimetostat_20AACR_20Poster_201.pdf)

<a id="topic-2.1.2.6.2-6"></a>

### Preclinical chromatin and lineage effects

> “Rinzimetostat restored access to AR binding motifs and restricted accessibility at sites associated with lineage plasticity in preclinical prostate cancer models, supporting a mechanism that reinforces AR dependence and limits tumor adaptation.”
> “KLK2 and STEAP1 luminal markers increased following rinzimetostat treatment in preclinical studies.”

Source: [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)

<a id="topic-2.1.2.6.2-7"></a>

### Preclinical single-agent activity in an enzalutamide-resistant model

> “ORIC-944 demonstrates strong single agent activity in enzalutamide-resistant, AR-v7+ prostate cancer xenograft model, 22Rv1”

Source: [Daemen et al. (2021)](https://oricpharma.com/wp-content/uploads/2021/03/ORIC-944-AACR2021-Abstract1131-FINAL.pdf)

<a id="topic-2.1.2.6.2-8"></a>

### Preclinical activity in EZH2 inhibitor-resistant settings

> “Prostate cancer cells that rapidly developed resistance to mevrometostat acquired a mutation in EZH2 against which rinzimetostat potency was maintained; no emergence of rinzimetostat-resistant cells was observed.”

Source: [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)

> “Rinzimetostat retained antitumor activity in prostate cancer cells with overexpressed EZH1 in vitro, while potency was diminished for mevrometostat or tazemetostat.”

Source: [ORIC Pharmaceuticals AACR preclinical data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-data-to-support-the-potential-of-rinzimetostat-across-prostate-cancer-and-in-emerging-resistance-settings-at-the-2026-american-association-for-cancer-re/)

<a id="topic-2.1.2.6.2-9"></a>

### Nonclinical toxicology: hematologic tumorigenesis in rats

> “No hematologic tumorigenesis was observed in the rinzimetostat rat toxicology study, in contrast to rat tumorigenesis demonstrated with EZH2 inhibitor tazemetostat; these results are consistent with mouse genetic studies of PRC2 components and suggest the tumorigenesis risk may be elevated with selective EZH2 targeting.”

Source: [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)

> “EED genetic deletion in mice did not induce hematologic malignancy, consistent with rinzimetostat 13-week rat GLP tox study demonstrating no tumorigenesis.”

Source: [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
